Clinical Trials Browser

High-risk Non-muscle Invasive Bladder Cancer × Injections × Clear all

NCT06378242 2024-07-11

To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2

Phase 1/2 Recruiting

High-risk Non-muscle Invasive Bladder Cancer